Lynsight

Lynsight is a Finish company with the mission to empower families and healthcare professionals to make better-informed decisions for cancer prevention. The start-up has developed an innovative and easy-to-use diagnostic method that reliably detects MMR deficiency, a hallmark of Lynch syndrome. With a prevalence of 1 in 279 people, it is the world’s most common inherited cancer predisposition, which causes a highly increase lifetime risk for cancer.

By delivering predictive and accurate results with a fast, unique and cost-efficient method, its cutting-edge product DiagMMR has the potential to save thousands of lives and to become the new global standard for Lynch syndrome detection.

DiagMMR aids the diagnosis of Lynch syndrome from a non-malignant tissue sample before tumors appear making it predictive instead of reactive. Moreover, it is a single functional test replacing the current large array of tests and delivers results that are easy to interpret reducing uncertainty.

The start-up originated in high-level academic research by its founder Prof. Minna Nyström and was spun out from the University of Helsinki in 2013. Since its incorporation, the start-up grew constantly and is planning to enter the US market after FDA approval 2025. Lynsight is located in Helsinki, Finland and joined NOME in 2020.